Dana L Dolce, NP
Nurse Practitioner · Hackensack
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 20 years
- Graduated 2006
Offices
2 locations · Hackensack Meridian Health Medical Group - Specialty Care PC · 1,901 clinicians in this group
Hospitals listed: Jersey Shore University Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dana L Dolce’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Jersey Shore University Medical CenterNeptune, NJAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Hackensack Meridian Health, which runs 13 hospitalsPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.36 (0.97 to 1.76) · 16,075 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 15.8 (12.7 to 19.5) · 242 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 131.68 (99.19 to 164.17) · 270 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.187, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.338, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.273, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.213, Oct 2024 – Sep 2025
See every measure and the patient survey for Jersey Shore University Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.36 (0.97 to 1.76) · 16,075 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 15.8 (12.7 to 19.5) · 242 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 131.68 (99.19 to 164.17) · 270 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.338 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.273 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.213 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.62 (0 to 1.37) · 3,079 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.85 to 1.25) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.3 · 451 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.3 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 432 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.4 · 1,348 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 1,017 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 691 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 6,607 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0.03 to 0.34) · 17,460 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.08 to 0.4) · 18,371 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.5 (1.08 to 3.92) · 5,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.95 (0 to 2.1) · 2,098 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.21 (2.16 to 4.26) · 5,002 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.31 (2.78 to 9.84) · 2,134 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.16 (2.42 to 7.9) · 2,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.37 (1.05 to 3.7) · 903 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 121 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 1.155 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.9 · 637 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 1,546 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -12.3 · 693 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 32.8 · 1,560 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 6 · 1,038 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.6 · 1,027 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.8 to 5.8) · 242 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 125 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 373 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.4 · 256 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.4 (10.9 to 19.1) · 469 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 1,064 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,231 patients answered, 21% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$17,745
Medicare paid this office $17,745 for 54 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 26 | $9,559 | $127 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 19 | $2,225 | $31 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 20 | $2,166 | $35 |
| Return visit (30+ min) | 20 | $1,741 | $79 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,175 | $90 |
See all 6 services
| Long return visit (40+ min) | 26 | $9,559 | $127 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 19 | $2,225 | $31 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 20 | $2,166 | $35 |
| Return visit (30+ min) | 20 | $1,741 | $79 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,175 | $90 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 17 | $230 | $12 |
Who their Medicare patients are
54 Original Medicare patients in 2024. Average age 71 · Women 32% · Health risk score 1.26. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 74% · Depression 46% · Coronary heart disease 43% · Diabetes 33% · Atrial fibrillation 20%.
The office billed $84,555, Medicare allowed $22,798 and paid $17,745; for 273 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 54 | 273 | 71 | 1.26 | $84,555 | $17,745 |
| 2023 | 42 | 207 | 69 | 1.58 | $53,730 | $10,638 |
| 2022 | 53 | 115 | 72 | 1.76 | $36,805 | $7,177 |
| 2021 | 49 | 80 | 71 | 2.75 | $20,177 | $6,311 |
| 2020 | 35 | 65 | 73 | 3.06 | $14,596 | $4,479 |
| 2019 | 13 | 19 | 73 | 5.63 | $4,164 | $1,169 |
| 2017 | 49 | 79 | 67 | 1.53 | $24,984 | $3,061 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 33 | $4,161 | $82 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 12 | $1,891 | $30 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 15 | $1,646 | $34 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 16 | $269 | $13 |
2022: 2 services
| Return visit (30+ min) | 37 | $4,460 | $87 |
| Short return visit (20+ min) | 11 | $675 | $52 |
2021: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $1,544 | $53 |
2020: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $2,458 | $77 |
2017: 2 services
| Electronic analysis reprogramming and refill of spinal canal drug infusion pump by physician | 11 | $993 | $34 |
| Short return visit | 14 | $270 | $17 |
Drugs they prescribed that Part D paid
$439,545
Pharmacies billed $439,545 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (98 of 1,375) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%.
1,221 generic and 154 brand-name prescriptions · $439,545 in drug cost · 16 antibiotic prescriptions to 12 people · 45 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Austedo | None | 19 | $188,180 | $9,904 |
| Nuplazid | Parkinson's psychosis | 14 | $66,920 | $4,780 |
| Rytary | Parkinson's | 64 | $56,927 | $889 |
| Carbidopa-Levodopa | None | 256 | $13,773 | $54 |
| Entacapone | None | 27 | $8,515 | $315 |
See all 29 drugs
| Austedo | None | 19 | $188,180 | $9,904 |
| Nuplazid | Parkinson's psychosis | 14 | $66,920 | $4,780 |
| Rytary | Parkinson's | 64 | $56,927 | $889 |
| Carbidopa-Levodopa | None | 256 | $13,773 | $54 |
| Entacapone | None | 27 | $8,515 | $315 |
| Carbidopa-Levodopa Er | None | 28 | $2,810 | $100 |
| Primidone | None | 71 | $2,777 | $39 |
| Quetiapine | None | 28 | $1,715 | $61 |
| Amantadine | None | 19 | $1,329 | $70 |
| Mirtazapine | None | 51 | $1,296 | $25 |
| Rasagiline Mesylate | None | 12 | $1,179 | $98 |
| Donepezil | None | 21 | $1,069 | $51 |
| Rivastigmine | None | 11 | $935 | $85 |
| Clonazepam | None | 86 | $759 | $9 |
| Oxycodone-Acetaminophen | None | 31 | $743 | $24 |
| Gabapentin | None | 35 | $742 | $21 |
| Pregabalin | None | 24 | $734 | $31 |
| Trazodone | None | 21 | $653 | $31 |
| Topiramate | None | 13 | $617 | $47 |
| Ropinirole | None | 13 | $521 | $40 |
| Alprazolam | None | 79 | $481 | $6 |
| Tizanidine | None | 14 | $412 | $29 |
| Lorazepam | None | 48 | $389 | $8 |
| Escitalopram | None | 17 | $377 | $22 |
| Tramadol | None | 42 | $282 | $7 |
| Methylphenidate | None | 19 | $188 | $10 |
| Duloxetine | None | 11 | $172 | $16 |
| Sertraline | None | 17 | $114 | $7 |
| Diazepam | None | 14 | $96 | $7 |
Year by year
| 2024 | 1,375 | 375 | 7% (98) | 11% | $439,545 |
| 2023 | 1,412 | 367 | 8% (108) | None | $544,902 |
| 2022 | 575 | 263 | 11% (62) | 7% | $127,281 |
| 2021 | 39 | 29 | 33% (13) | None | $7,899 |
| 2019 | 14 | None | None | None | $1,039 |
| 2018 | 15 | 11 | None | None | $2,809 |
| 2017 | 187 | 62 | 31% (58) | None | $4,432 |
| 2016 | 121 | 64 | 34% (41) | 0% | $1,170 |
| 2015 | 168 | 78 | 38% (63) | 7% | $6,512 |
| 2014 | 193 | 95 | 37% (72) | 6% | $3,198 |
| 2013 | 122 | 59 | 39% (47) | None | $1,663 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 28 drugs
| Nuplazid | Parkinson's psychosis | 24 | $156,445 | $6,519 |
| Ingrezza | None | 12 | $100,908 | $8,409 |
| Rytary | Parkinson's | 58 | $100,624 | $1,735 |
| Carbidopa-Levodopa | None | 237 | $16,860 | $71 |
| Entacapone | None | 16 | $5,185 | $324 |
| Donepezil | None | 52 | $3,067 | $59 |
| Ropinirole Er | None | 11 | $3,033 | $276 |
| Primidone | None | 48 | $2,401 | $50 |
| Pregabalin | None | 21 | $2,349 | $112 |
| Amantadine | None | 28 | $2,115 | $76 |
| Mirtazapine | None | 38 | $2,092 | $55 |
| Tizanidine | None | 21 | $1,516 | $72 |
| Carbidopa-Levodopa Er | None | 24 | $1,129 | $47 |
| Clonazepam | None | 73 | $1,075 | $15 |
| Oxycodone-Acetaminophen | None | 33 | $896 | $27 |
| Lorazepam | None | 71 | $869 | $12 |
| Alprazolam | None | 121 | $845 | $7 |
| Gabapentin | None | 50 | $806 | $16 |
| Misoprostol | None | 12 | $435 | $36 |
| Methylphenidate | None | 32 | $430 | $13 |
| Propranolol | None | 17 | $411 | $24 |
| Escitalopram | None | 22 | $411 | $19 |
| Tramadol | None | 38 | $228 | $6 |
| Diazepam | None | 30 | $198 | $7 |
| Sertraline | None | 20 | $192 | $10 |
| Oxycodone | None | 20 | $152 | $8 |
| Cyclobenzaprine | None | 21 | $121 | $6 |
| Acetaminophen-Codeine | None | 11 | $38 | $3 |
2022: 16 drugs
| Rytary | Parkinson's | 19 | $20,924 | $1,101 |
| Carbidopa-Levodopa | None | 92 | $9,307 | $101 |
| Clonazepam | None | 24 | $896 | $37 |
| Amantadine | None | 13 | $764 | $59 |
| Primidone | None | 15 | $709 | $47 |
| Gabapentin | None | 25 | $709 | $28 |
| Quetiapine | None | 14 | $510 | $36 |
| Alprazolam | None | 28 | $413 | $15 |
| Oxycodone-Acetaminophen | None | 19 | $390 | $21 |
| Levetiracetam | None | 11 | $296 | $27 |
| Lorazepam | None | 24 | $282 | $12 |
| Donepezil | None | 17 | $276 | $16 |
| Methylphenidate | None | 12 | $163 | $14 |
| Tramadol | None | 16 | $127 | $8 |
| Diazepam | None | 19 | $98 | $5 |
| Oxycodone | None | 12 | $84 | $7 |
2017: 4 drugs
| Carbidopa-Levodopa | 16 | $684 | $43 |
| Acetaminophen-Codeine | 28 | $211 | $8 |
| Hydrocodone-Acetaminophen | 14 | $196 | $14 |
| Diazepam | 13 | $31 | $2 |
2016: 2 drugs
| Acetaminophen-Codeine | 31 | $192 | $6 |
| Cephalexin | 11 | $55 | $5 |
2015: 5 drugs
| Oxycodone-Acetaminophen | 30 | $624 | $21 |
| Methylprednisolone | 13 | $237 | $18 |
| Acetaminophen-Codeine | 21 | $125 | $6 |
| Cephalexin | 15 | $75 | $5 |
| Famotidine | 11 | $59 | $5 |
2014: 7 drugs
| Oxycodone-Acetaminophen | 25 | $436 | $17 |
| Methylprednisolone | 13 | $289 | $22 |
| Acetaminophen-Codeine | 25 | $150 | $6 |
| Cyclobenzaprine | 11 | $126 | $11 |
| Cephalexin | 20 | $111 | $6 |
| Hydromorphone | 15 | $101 | $7 |
| Diazepam | 20 | $74 | $4 |
2013: 3 drugs
| Methylprednisolone | 11 | $253 | $23 |
| Oxycodone-Acetaminophen | 23 | $186 | $8 |
| Cyclobenzaprine | 19 | $181 | $10 |
Money from drug and device companies
$1,863 in 2025
| 2025 | 24 | 95 | None | $1,863 |
| 2024 | 20 | 63 | None | $1,528 |
| 2023 | 7 | 28 | None | $724 |
| 2022 | 5 | 26 | None | $952 |
| 2021 | 1 | 5 | None | $137 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | General - Dbs | $361 | 8 payments
|
| Ucb | Briviact | $347 | 22 payments
|
| Medtronic | Percept PC Brainsense | $193 | 13 payments
|
| InSightec | Exablate | $134 | 3 payments
|
| Neurelis | Valtoco | $97 | 6 payments
|
| Argenx US | Vyvgart Hytrulo | $83 | 5 payments
|
See all 95 published payments
| Boston Scientific | Meals · 2025-12-19 | General - Dbs | $83 |
| Medtronic | Meals · 2025-12-18 | Stealthstation S8 Platform | $39 |
| Boston Scientific | Meals · 2025-12-12 | General - Dbs | $125 |
| InSightec | Meals · 2025-12-11 | Exablate | $83 |
| Medtronic | Meals · 2025-11-12 | Percept PC Brainsense | $14 |
| Ucb | Meals · 2025-11-05 | Rystiggo | $16 |
| InSightec | Meals · 2025-10-30 | Exablate | $26 |
| Abbvie | Meals · 2025-10-24 | Vyalev | $14 |
| SK Life Science | Meals · 2025-10-08 | None | $17 |
| Lundbeck | Meals · 2025-10-07 | Vyepti | $19 |
| Ucb | Meals · 2025-10-02 | Rystiggo | $17 |
| Medtronic | Meals · 2025-10-01 | Percept PC Brainsense | $4 |
| Merz Pharmaceuticals | Meals · 2025-09-26 | Xeomin | $14 |
| Ucb | Meals · 2025-09-23 | Nayzilam | $18 |
| Medtronic | Meals · 2025-09-19 | Percept PC Brainsense | $5 |
| Medtronic | Meals · 2025-09-12 | Percept PC Brainsense | $5 |
| Medtronic | Meals · 2025-09-09 | Percept PC Brainsense | $5 |
| Argenx US | Meals · 2025-09-09 | Vyvgart Hytrulo | $18 |
| Tonix Medicines | Meals · 2025-09-08 | Zembrace Symtouch | $15 |
| Teva Pharmaceuticals USA | Meals · 2025-09-03 | Austedo Xr | $15 |
| InSightec | Meals · 2025-08-26 | Exablate | $25 |
| Boston Scientific | Meals · 2025-08-15 | General - Dbs | $5 |
| Neurocrine BioSciences | Meals · 2025-08-15 | Ingrezza | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-13 | None | $14 |
| Neurelis | Meals · 2025-08-11 | Valtoco | $16 |
| Servier Pharmaceuticals | Meals · 2025-08-07 | None | $19 |
| Biogen | Meals · 2025-08-06 | Qalsody | $18 |
| Argenx US | Meals · 2025-07-29 | Vyvgart Hytrulo | $17 |
| Neurelis | Meals · 2025-07-28 | Valtoco | $17 |
| Ucb | Meals · 2025-07-23 | Nayzilam | $19 |
| Neurocrine BioSciences | Meals · 2025-07-17 | Ingrezza | $18 |
| SK Life Science | Meals · 2025-07-16 | None | $16 |
| Neurelis | Meals · 2025-07-14 | Valtoco | $16 |
| Jazz Pharmaceuticals | Meals · 2025-07-09 | Epidiolex | $19 |
| Lundbeck | Meals · 2025-07-08 | Vyepti | $19 |
| Tonix Medicines | Meals · 2025-07-01 | Zembrace Symtouch | $17 |
| Ucb | Meals · 2025-06-25 | Nayzilam | $19 |
| Boston Scientific | Meals · 2025-06-16 | General - Dbs | $6 |
| Medtronic | Meals · 2025-06-16 | Percept PC Brainsense | $5 |
| Ucb | Meals · 2025-06-13 | Zilbrysq | $18 |
| Ucb | Meals · 2025-06-11 | Fintepla | $18 |
| Boston Scientific | Meals · 2025-06-05 | General - Dbs | $102 |
| Medtronic | Meals · 2025-06-05 | Percept PC Brainsense | $44 |
| Teva Pharmaceuticals USA | Meals · 2025-05-28 | Austedo Xr | $17 |
| Argenx US | Meals · 2025-05-21 | Vyvgart Hytrulo | $16 |
| Ucb | Meals · 2025-05-16 | Rystiggo | $0 |
| Ucb | Meals · 2025-05-16 | Rystiggo | $12 |
| Servier Pharmaceuticals | Meals · 2025-05-15 | None | $22 |
| Ucb | Meals · 2025-05-14 | Briviact | $0 |
| Ucb | Meals · 2025-05-14 | Briviact | $18 |
| Tonix Medicines | Meals · 2025-05-13 | Zembrace Symtouch | $16 |
| Amneal Pharmaceuticals | Meals · 2025-05-09 | Crexont | $18 |
| Ucb | Meals · 2025-05-08 | Fintepla | $18 |
| Neurelis | Meals · 2025-04-30 | Valtoco | $17 |
| Medtronic | Meals · 2025-04-28 | Percept PC Brainsense | $5 |
| Medtronic | Meals · 2025-04-22 | Percept PC Brainsense | $22 |
| LivaNova USA | Meals · 2025-04-18 | Vns Therapy Sentiva Model 1000 Generator | $21 |
| Tonix Medicines | Meals · 2025-04-17 | Zembrace Symtouch | $14 |
| Biogen | Meals · 2025-04-16 | Qalsody | $19 |
| Neurelis | Meals · 2025-04-14 | Valtoco | $16 |
| Ucb | Meals · 2025-04-11 | Rystiggo | $16 |
| Abbott Laboratories | Meals · 2025-04-10 | Infinity | $20 |
| Ucb | Meals · 2025-04-09 | Briviact | $19 |
| Boston Scientific | Meals · 2025-04-04 | General - Dbs | $28 |
| Novocure | Meals · 2025-04-04 | Optune Gio | $19 |
| Ucb | Meals · 2025-04-03 | Fintepla | $19 |
| Medtronic | Meals · 2025-04-02 | Percept PC Brainsense | $38 |
| Aucta Pharmaceuticals | Meals · 2025-03-31 | Motpoly Xr | $16 |
| Tanabe Pharma America | Meals · 2025-03-28 | Radicava | $16 |
| Neurocrine BioSciences | Meals · 2025-03-26 | Ingrezza | $17 |
| Lundbeck | Meals · 2025-03-25 | Vyepti | $14 |
| Medtronic | Meals · 2025-03-24 | Percept PC Brainsense | $5 |
| Servier Pharmaceuticals | Meals · 2025-03-21 | None | $18 |
| SpringWorks Therapeutics | Meals · 2025-03-19 | Gomekli | $19 |
| Neurocrine BioSciences | Meals · 2025-03-14 | Ingrezza | $17 |
| Ucb | Meals · 2025-03-12 | Briviact | $18 |
| Teva Pharmaceuticals USA | Meals · 2025-03-06 | Ajovy | $16 |
| Neurelis | Meals · 2025-03-05 | Valtoco | $16 |
| SK Life Science | Meals · 2025-03-05 | None | $16 |
| Medtronic | Meals · 2025-03-03 | Percept PC Brainsense | $2 |
| Ucb | Meals · 2025-02-28 | Rystiggo | $17 |
| Ucb | Meals · 2025-02-26 | Fintepla | $16 |
| Jazz Pharmaceuticals | Meals · 2025-02-19 | Epidiolex | $14 |
| Argenx US | Meals · 2025-02-18 | Vyvgart | $16 |
| Amneal Pharmaceuticals | Meals · 2025-02-14 | Crexont | $19 |
| Ucb | Meals · 2025-02-12 | Briviact | $17 |
| Servier Pharmaceuticals | Meals · 2025-02-07 | None | $15 |
| Boston Scientific | Meals · 2025-02-04 | General - Dbs | $7 |
| Boston Scientific | Meals · 2025-02-04 | General - Dbs | $5 |
| Argenx US | Meals · 2025-01-27 | Vyvgart | $16 |
| Ucb | Meals · 2025-01-22 | Briviact | $18 |
| Ucb | Meals · 2025-01-17 | Rystiggo | $17 |
| Tanabe Pharma America | Meals · 2025-01-16 | Radicava | $17 |
| Jazz Pharmaceuticals | Meals · 2025-01-15 | Epidiolex | $15 |
| Ucb | Meals · 2025-01-08 | Briviact | $18 |
See earlier years (2024, 2023, 2022, 2021)
2024: $1,528
| Medtronic | Percept PC Brainsense | $364 | 7 payments
|
| Abbott Laboratories | Infinity | $361 | 5 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $184 | 12 payments
|
| Ucb | Fintepla | $140 | 10 payments
|
| Lundbeck | Vyepti | $88 | 5 payments
|
| Mitsubishi Tanabe Pharma America | Radicava | $47 | 3 payments
|
| Servier Pharmaceuticals | Voranigo | $47 | 3 payments
|
| SK Life Science | None | $46 | 3 payments
|
| Merz Pharmaceuticals | Xeomin | $36 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $34 | 2 payments
|
| Neurelis | Valtoco | $30 | 2 payments
|
| Argenx US | Vyvgart | $19 | 1 payment
|
| Lilly USA | Emgality | $18 | 1 payment
|
| Electromed | Smartvest | $18 | 1 payment
|
| InSightec | Exablate | $18 | 1 payment
|
| Amneal Pharmaceuticals | Rytary | $17 | 1 payment
|
| Kyowa Kirin | Nourianz | $17 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $16 | 1 payment
|
| Tonix Medicines | Zembrace Symtouch | $15 | 1 payment
|
| SpringWorks Therapeutics | None | $14 | 1 payment
|
2023: $724
| Abbott Laboratories | Infinity | $231 | 6 payments
|
| InSightec | Exablate | $214 | 6 payments
|
| Medtronic | Sensight | $127 | 7 payments
|
| Corcept Therapeutics | Korlym | $60 | 3 payments
|
| Amneal Pharmaceuticals | Rytary | $47 | 3 payments
|
| Teva Pharmaceuticals USA | Austedo | $30 | 2 payments
|
| Eisai | Leqembi | $14 | 1 payment
|
2022: $952
| Abbott Laboratories | Infinity | $478 | 12 payments
|
| Medtronic | Sensight | $294 | 7 payments
|
| Boston Scientific | General - Dbs | $87 | 4 payments
|
| Integra LifeSciences | Codman Certas | $76 | 2 payments
|
| Amneal Pharmaceuticals | Rytary | $17 | 1 payment
|
2021: $137
| Abbott Laboratories | Proclaim Ipg | $137 | 5 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 79.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1548329865
- Licence
- CA 95004147, PA SP009256
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LA2200X (363LA2200X)
- Mailing address
- 1804 Embarcadero Rd, Ste 100, Palo Alto, CA, 94303
- NPI first listed
- 2006-12-06
- NPI last updated
- 2016-06-20
This is when the NPI record was last certified, not a medical board exam.